Sitavitae Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Sitagliptin

Indications/Uses

Monotherapy as an adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM. Patients w/ type 2 DM to improve glycemic control in combination w/ metformin, sulfonylurea or PPARγ agonist (eg, thiazolidinediones) when monotherapy, w/ diet & exercise, does not provide adequate glycemic control. Patients w/ type 2 DM to improve glycemic control in combination w/ metformin & sulfonylurea when dual therapy w/ these agents, w/ diet & exercise, does not provide adequate glycemic control. Add-on to insulin (w/ or w/o metformin) when diet & exercise plus stable insulin dose do not provide adequate glycemic control.

Dosage/Direction for Use

100 mg once daily. Renal impairment: eGFR ≥30 to <45 mL/min/1.73 m² 50 mg once daily, ≥15 to <30 mL/min/1.73 m² or ESRD (eGFR <15 mL/min/1.73 m²) including those requiring hemodialysis or peritoneal dialysis 25 mg once daily.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Regulatory Classification

POM

Presentation/Packing

Form

Sitavitae FC tab 100 mg

Packing/Price

1's

Form

Sitavitae FC tab 50 mg

Packing/Price

1's

Sitavitae

sitagliptin

Manufacturer:

SAG Manufacturing S.L.U.